Circio invites to live webcast on 1 September...
- Circio is publishing its first half 2026 report on 31 August 2026
- Circio management will provide a financial and corporate update in a live webcast at 10:00am CEST on 1 September 2026
- The webcast will include a presentation of R&D progress, including new circVec results generated for heart and CNS gene therapy, as well as the in vivo CAR-T program
Oslo, Norway, 25 August 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, will host a live webcast from its R&D headquarter in Stockholm, Sweden, at 10:00am CEST on Tuesday 1 September 2026.
In the webcast, CEO Dr. Erik D Wiklund and CFO Dr. Lubor Gaal will provide a corporate update including a summary of first half 2026 financials and an overview of Circio´s extensive business development activities. CTO Dr. Thomas B Hansen will present the most recent circVec pre-clinical results, including promising new in vivo data generated in heart and CNS gene therapy, as well as advances on the in vivo CAR-T program.
The first half year 2026 report will be published on 31 August 2026, and further information and presentation materials will be published ahead of the webcast on 1 September 2026.
The webcast will be held in English. Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast.
Time: 10:00 CEST on Tuesday 1 September 2026
Click here to access Teams webcast
Meeting ID: 343 877 779 042 528
Passcode: MD3Pv2nP
A recording of the webcast will be made available on the Circio webpage and the presentation materials are attached hereto.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.